Medutest result on a Tianjin semaglutide lot lands 2.4 points below the supplier’s figure
The result is unremarkable. What the report omits is not.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 25 of 48 of this archive, newest first.
The result is unremarkable. What the report omits is not.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Follow the resin, not the catalogue.
Two signatures — one who performed the work, one who approved its release — are the ordinary regulated convention and are almost unknown here.
Follow the resin, not the catalogue.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The route did not close because of a rule about peptides.
The route did not close because of a rule about peptides.
The route did not close because of a rule about peptides.
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
Follow the resin, not the catalogue.
The route did not close because of a rule about peptides.
Follow the resin, not the catalogue.
The route did not close because of a rule about peptides.
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
The route did not close because of a rule about peptides.
Follow the resin, not the catalogue.
The route did not close because of a rule about peptides.
The result is unremarkable. What the report omits is not.
The route did not close because of a rule about peptides.